EMA Wants to Know if Pharma is Ready for Brexit

News
Article

The agency is sending a survey out to pharmaceutical companies in the UK to gain information on their preparedness for Brexit.

The European Medicines Agency announced on Jan. 23, 2018 that it was performing a survey to see if pharmaceutical companies are ready for the United Kingdom’s withdrawal from the European Union, also known as Brexit. The survey will also ask companies to identify any concerns they may have.

Specifically, EMA plans to use the survey to identify companies that may need help addressing concerns that have risen from Brexit. EMA and the European Commission will also use survey results to plan for needed resources. The agency hopes the survey may also urge companies that have not yet taken action regarding Brexit-related issues to start doing so.

The survey is being sent to marketing authorization holders located in the UK, or companies who have quality control, batch release, and/or import manufacturing sites or a qualified person for pharmacovigilance (QPPV) or pharmacovigilance system master file (PSMF) in the UK. Companies will be asked about their plans to submit transfers, notifications or variations to their marketing authorizations in the context of Brexit.

The deadline for completing the survey is Feb. 9, 2018. Results will be shared with the European Commission and a summary will be published on EMA’s website.

Source: EMA

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.